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Abstract
Introduction: Angiogenesis plays a critical role in synovial inflammation and joint destruction in rheumatoid
arthritis (RA). Vascular endothelial growth factor A (VEGF-A) and angiopoietins are two important mediators of
synovial angiogenesis. We have previously developed a novel chimeric decoy receptor, namely, double-
antiangiogenic protein (DAAP), which can both bind VEGF-A and angiopoietins and block their actions. This study
was performed to evaluate the antiarthritic effect of DAAP and the combination effect with the tumor necrosis
factor a (TNF-a) inhibitor in collagen-induced arthritis (CIA).
Methods: Recombinant DAAP, VEGF-Trap, Tie2-Fc and dimeric Fc proteins were produced and purified from CHO
cells in large-scale bioreactors. CIA was induced in DBA/1 mice with type II collagen. The preventive effect of DAAP
was determined and compared with other decoy receptors such as VEGF-Trap or Tie2-Fc, which block VEGF-A or
angiopoietins, respectively. The clinical, radiographic, pathologic and immunohistochemical analyses were
performed in CIA mice. The levels of matrix metalloprotease 3 (MMP-3) and interleukin 1b (IL-1b) were quantified
by enzyme-linked immunosorbent assay, and receptor activator of nuclear factor B ligand (RANKL) mRNA levels
were measured by polymerase chain reaction. Finally, we investigated the combination effects of DAAP with a low
dose of TNF-a decoy receptor (etanercept 10 mg/kg).
Results: On the basis of clinical and radiographic evaluation, DAAP had a much greater inhibitory effect than
VEGF-Trap or Tie2-Fc on arthritis severity and bone destruction. These inhibitory effects were accompanied by
significantly diminishing pathologic abnormalities, CD31-positive vasculature and synovial infiltration by F4/80-
positive macrophages. The levels of MMP-3, IL-1b and RANKL were much lower in the DAAP-injected group than
those of the control. Furthermore, DAAP showed a therapeutic effect and a combination effect with etanercept
when injected after arthritis onset in established CIA.
Conclusions: DAAP has not only potent prophylactic effects on both inflammation and bone destruction but also
therapeutic effects, alone and in combination with a TNF-a inhibitor in CIA mice. These results suggest that DAAP
could be used as an effective new therapeutic agent for RA.
* Correspondence: gykoh@kaist.ac.kr; goldgu@gnu.ac.kr
† Contributed equally
2National Research Laboratory of Vascular Biology and Stem Cells and
Graduate School of Biomedical Science and Engineering, Korea Advanced
Institute of Science and Technology (KAIST), 373-1 Guseong-dong, Daejeon,
305-701, South Korea
3Department of Internal Medicine and Institute of Health Science,
Gyeongsang National University School of Medicine, 79 Gangnam-Ro, Jinju,
660-702, South Korea
Full list of author information is available at the end of the article
Hah et al. Arthritis Research & Therapy 2013, 15:R85
http://arthritis-research.com/content/15/4/R85
© 2013 Hah et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Introduction
Rheumatoid arthritis (RA) is the most common inflamma-
tory arthritis and a major cause of disability due to joint
destruction and permanent deformity [1]. Angiogenesis
plays a critical role in RA by promoting inflammatory cell
infiltration and the development of pannus, aggressive
tumorlike fibrovascular granulation tissue, which even-
tually leads to extensive joint destruction [2,3]. Thus, the
inhibition of angiogenesis, which has long been studied in
the treatment of malignancies, is emerging as a potential
therapeutic approach for RA [3,4].
Multiple mediators have been implicated in the process
of angiogenesis [5,6]. Among them, vascular endothelial
growth factor A (VEGF-A) and VEGF receptor (VEGFR)
are the most intensively studied key regulators of angio-
genesis in inflammation [7]. VEGF-A also contributes
directly to joint destruction by stimulating osteoclasts
through upregulation of receptor activators of nuclear
factor B (RANK) in endothelial cells [8]. Thus, numer-
ous therapies have been developed that specifically target
these molecules in RA [4]. However, despite some posi-
tive findings, recent clinical trials in cancer patients trea-
ted with VEGF-A inhibitors have revealed disadvantages
such as insufficiency, resistance and toxicities [9-11].
Angiopoietins, including angiopoietin 1 (Ang-1), Ang-2
and Ang-3/Ang-4, are other important angiogenic factors.
They interact with tyrosine kinase with immunoglobulin
and epidermal growth factor homology domain 2 (Tie2)
receptors [12]. Numerous studies have demonstrated that
Ang-1, Ang-2 and Tie2 levels are increased in RA tissues
and that blocking them inhibits angiogenesis as well as
arthritis development and progression in collagen-induced
arthritis (CIA) [13-19]. In particular, many reports have
shown that Ang-2 is the major angiopoietin that enhances
tumor angiogenesis, along with several other growth fac-
tors, such as VEGF-A [12,20,21]. Indeed, the upregulation
of angiopoietins may be a major mechanism underlying
the inadequate therapeutic effects of VEGF-A pathway
blockage [9,22]. Therefore, the discovery of a new agent,
which could simultaneously block both VEGF-A and
angiopoietins, will be needed to more effectively suppress
pathologic angiogenesis in cancer and RA.
We have developed a novel chimeric decoy receptor,
double-antiangiogenic protein (DAAP), which can bind
the VEGF-A, placenta growth factor (PIGF) and the
angiopoietins and thereby simultaneously block their
actions [22]. A previous report showed that DAAP was
highly effective for suppressing tumor angiogenesis and
metastasis in implanted and spontaneous solid tumors, as
well as for reducing ascites formation and vascular leak-
age in an ovarian carcinoma model, compared with
VEGF-Trap or Tie2-Fc, which block only VEGF or angio-
poietin signaling, respectively [22]. However, the question
whether DAAP might be useful in RA has remained
unanswered to date. Thus, we examined whether DAAP
might show higher potency than VEGF-Trap or Tie2-Fc
and whether it might represent a beneficial combinatory
effect when combined with TNF-a inhibitor in an experi-
mental model of RA.
Materials and methods
Generation of recombinant proteins
Recombinant proteins, including DAAP, VEGF-Trap,
Tie2-Fc and dimeric Fc (Fc), were produced as previously
described [22]. Briefly, the genes for DAAP, VEGF-Trap,
Tie2-Fc and Fc were inserted into pCMV-dhfr2, trans-
fected into dhfr-deficient CHO cells (DG44), selected with
G418 and amplified by sequential increases in methotrex-
ate. The clones with the highest production of each
recombinant protein were selected and further grown to
obtain suitable amounts of protein. Recombinant proteins
in supernatants were purified by column chromatography
with protein A agarose resin (OncogeneScience/Wilex,
Cambridge, MA, USA). After purification, recombinant
proteins were quantified using the Bradford assay and con-
firmed by Coomassie blue staining after SDS-PAGE.
Collagen-induced arthritis experiment
DBA/1 mice were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA), and male DBA/1 mice (seven to
nine weeks old) were immunized with 150 μg of bovine
collagen type II (Chondrex, Redmond, WA, USA) emulsi-
fied with an equal volume of Complete Freund’s Adjuvant
(Chondrex). The day of the first immunization was defined
as day 0. The mice were then boosted with an equal
amount of bovine collagen type II emulsified in Incom-
plete Freund’s Adjuvant on day 21. For the preventive
experiment, CIA mice were given intraperitoneal injec-
tions of phosphate-buffered saline (PBS), Fc, VEGF-Trap,
Tie2-Fc or DAAP (25 mg/kg, twice weekly) from day 21
to day 40. For the therapeutic experiment, following the
development of clinical arthritis (average arthritis score of
2) on day 26, CIA mice were randomized and given intra-
peritoneal injections of Fc, DAAP (25 mg/kg every two
days), etanercept (10 mg/kg every two days) or DAAP +
etanercept. Clinical arthritis scores were evaluated using a
scale of 0 to 3 for each paw with a total possible score of
12. Ankle thickness was measured with a caliper placed
across the ankle joint at the widest point. All experimental
animals used in this study were maintained under the pro-
tocol approved by Gyeongsang National University Institu-
tional Animal Care and Use Committee (GLA-080822-
M0060).
Radiological examination
Plain radiographs of the knees and feet were obtained
using a mammographic imager as previously described
[23]. The degree of joint destruction and bone erosion
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scored on a scale from 0 to 5, where 0 is no damage; 1 is
minor bone destruction observed in one enlightened spot;
2 is moderate change, two to four with spots in one area;
3 is marked changes, two to four spots in more than one
area; 4 is severe erosion afflicting the joints; and 5 is com-
plete destruction of the joints.
Histological and morphometric analyses
Fixed joint tissues were decalcified and embedded in
paraffin. Sections (5 µm) were stained with hematoxylin
and eosin and Safranin O. The joint sections were
scored for changes in synovial inflammation, pannus
formation, cartilage damage and bone erosion, all on a
0- to 3-point scale. CD31 and F4/80 were immunohisto-
chemically detected using a rabbit polyclonal antibody
against CD31 (Thermo Scientific, Waltham, MA, USA)
or a rat monoclonal antibody directed against F4/80
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
number of F4/80+ cells and CD31+ blood vessels were
counted in eight randomly selected high-power fields
(×400) for each knee and ankle joint.
Enzyme-linked immunosorbent assay
Ankle joints and serum were harvested at day 40 from the
CIA mice. The frozen joint tissues were pulverized in
liquid nitrogen, and total protein extracts from the ankle
joints were isolated from individual homogenized joints in
lysis buffer (mammalian protein extraction reagent; Pierce
Biotechnology, Rockford, IL, USA) containing Protease
Inhibitor Cocktail (Calbiochem/EMD Millipore, Billerica,
MA, USA). IL-1b, MMP-3 and VEGF were measured
using commercially available enzyme-linked immunosor-
bent assay kits according to the manufacturer’s instruc-
tions (R&D Systems, Minneapolis, MN, USA).
Reverse transcription polymerase chain reaction
Total RNA was isolated and transcribed into cDNA using
the iScript cDNA Synthesis Kit (Bio-Rad Laboratories,
Hercules, CA, USA) according to the manufacturer’s pro-
tocol. After denaturing at 85°C for five minutes and then
cooling to 4°C, cDNA was amplified using PCR. Two
microliters of denatured cDNA were amplified in a 50-μl
final volume containing 1 U of ExTaq DNA polymerase
(TaKaRa, Tokyo, Japan), 0.4 μM concentrations of each
primer, Taq polymerase buffer and 2 mM concentrations
of each deoxyribonucleotide triphosphate. PCR was per-
formed in a thermal cycler (Bio-Rad Laboratories) using a
program of 35 cycles at 95°C for 30 s, 56°C for 40 s and
72°C for 50 s with a final seven-minute extension at 72°C.
The sense primer for RANKL was 5’-CCAGCAT-
CAAAATCCCAAGTT-3’, and the antisense primer was
5’-TCAAGGTTCTCAGTGGCACAT-3’. The sense pri-
mer for glyceraldehyde 3-phosphate dehydrogenase was
5’-AATGCATCCTGCACCACCAA-3’, and the antisense
primer was 5’-GTAGCCATATTCATTGTCAT-3’. The
amplified products were subjected to electrophoresis on
1.2% agarose gel, and the results were visualized with ethi-
dium bromide staining.
Western blot analysis
Lysates were generated from ankle tissue in a radioim-
munoprecipitation assay lysis buffer (20 mM Tris, pH
7.5, 140 mM NaCl, 1 mM ethylenediaminetetraacetic
acid, 1% (vol/vol) Nonidet P-40, Protease Inhibitor
Cocktail). The homogenated tissue was centrifuged at
12,000 g for 20 min at 4°C to remove insoluble debris.
Equal amounts of the protein lysate were resolved on
reducing SDS polyacrylamide gels and then electrophor-
etically transferred onto a nitrocellulose membrane
(Amersham Pharmacia Biotech, Little Chalfont, UK).
After blocking for one hour with 5% skimmed milk in a
TBST buffer solution (10 mM Tris, 150 mM NaCl and
0.1% Tween 20), the membrane was incubated with pri-
mary antibodies against Ang-1 and Ang-2 (LifeSpan
Biosciences, Seattle, WA, USA), followed by incubation
with horseradish peroxidase-conjugated anti-rabbit
immunoglobulin G (IgG) (Santa Cruz Biotechnology).
The membrane was developed by SuperSignal West
Pico Chemiluminescent Substrate (Pierce Biotechnology)
and exposed to an X-ray film.
Statistics
Values are expressed as the mean ± SE. Fisher’s exact
test was used to analyze the differences in incidence
among groups. The Mann-Whitney U test was used to
analyze arthritic severity and the radiographic and histo-
logic findings. An unpaired Student’s t-test and one-way
analysis of variance were used to assess the other
results. P ≤ 0.05 was considered significant.
Results
Double-antiangiogenic protein exerts protective effects
against inflammation and bone destruction
The severity of CIA, such as cumulative incidence, a clin-
ical arthritis score and ankle thickness, indicated that
arthritis was significantly attenuated with VEGF-Trap,
Tie2-Fc and DAAP treatments compared with PBS or
control Fc (Figures 1A through 1D). Particularly, the
antiarthritic effect of DAAP was significantly greater than
that of VEGF-Trap (P < 0.01) (Figures 1C and 1D).
Severe bone erosion and joint damage were observed in
PBS- or Fc-injected mice (arrows), but mild to moderate
erosion (arrowheads) and periarticular osteopenia (aster-
isks) were observed in the mice injected with VEGF-Trap
or Tie2-Fc (Figure 2A). Notably, DAAP-treated CIA mice
showed minimal bone destruction and markedly
decreased radiological scores compared with mice treated
with VEGF-Trap or Tie2-Fc (P < 0.01) (Figure 2B). There
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was no difference in the suppressive effect on bone
destruction between the VEGF-Trap- and Tie2-Fc-
treated groups, although Tie2-Fc had a more potent inhi-
bitory effect on inflammatory aspects, such as joint swel-
ling and erythema. In comparison, DAAP showed potent
protective effects against both inflammation and bone
destruction.
The joints of Fc-injected CIA mice exhibited prominent
synovial inflammation, cartilage damage, pannus forma-
tion and bone erosion. In contrast, VEGF-Trap- or Tie2-
Fc-treated mice showed decreased pathological manifesta-
tions, and DAAP-treated mice exhibited dramatically
reduced pathological abnormalities (Figures 3A and 3B).
The histological scores for all parameters also showed
decreased pathological abnormalities in the VEGF-Trap-
or Tie2-Fc-treated groups and substantially fewer abnorm-
alities in the DAAP-treated group (Figure 3E). Consistent
with the results of our radiological findings, there was no
difference in the suppressive effect on bone erosion
between the VEGF-Trap and Tie2-Fc groups, although the
Figure 1 Preventive effect of double-antiangiogenic protein on collagen-induced arthritis. (A) Representative photographs showing the
gross features of mice hind paws at day 40. Collagen-induced arthritis (CIA) mice were given intraperitoneal injections of phosphate-buffered
saline (PBS), dimeric Fc (Fc), vascular endothelial growth factor (VEGF)-Trap, tyrosine kinase with immunoglobulin and epidermal growth factor
homology domain 2 (Tie2)-Fc or double-antiangiogenic protein (DAAP) (25 mg/kg twice weekly, n = 10 for each group) from days 21 to 40.
(B) Incidence of arthritis. (C) Arthritis scores. (D) Ankle thickness. Values are mean ± SE, n = 10 mice for each group. *P < 0.05, **P < 0.01.
Figure 2 Inhibitory effect of double-antiangiogenic protein on bone destruction in collagen-induced arthritis. (A) Representative
radiographs of hind paws. Note the severe bone erosions and joint damage (arrows), mild to moderate erosions (arrowheads) and periarticular
osteopenia (asterisks). (B) Quantitative analysis of bone destruction. DAAP: Double-antiangiogenic protein; PBS: Phosphate-buffered saline; PCR:
polymerase chain reaction; Tie2: Tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2; VEGF: Vascular
endothelial growth factor. Values are mean ± SE, n = 20 for each group. *P < 0.05, **P < 0.01.
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Tie2-Fc group displayed less synovial inflammation than
the VEGF-Trap group (Figure 3E).
Double-antiangiogenic protein acts primarily by
inhibiting blood vessel formation
Treatment with DAAP, VEGF-Trap or Tie2-Fc resulted in
a decrease in CD31+ blood vessels and F4/80+ macrophages
in the joint synovium compared with Fc (Figures 3C, D, F
and 3G). Notably, the inhibitory effect of DAAP on blood
vessel formation and macrophage infiltration was sig-
nificantly greater than that of VEGF-Trap (P < 0.01)
(Figures 3F and 3G).
MMP-3 and IL-1b levels were decreased in mice
injected with DAAP, VEGF-Trap and Tie2-Fc (Figures 4A
through 4C). The levels of both MMP-3 and IL-1b in the
serum and joint tissue of Tie2-Fc-treated CIA mice were
Figure 3 Double-antiangiogenic protein reduces pathologic findings, infiltration of F4/80+ macrophages and vessel formation in
collagen-induced arthritis. (A) and (B) Representative sections of ankle joints stained with hematoxylin and eosin and Safranin O, respectively
(bars = 500 μm). (C) and (D) Representative images of synovium stained with F4/80 and CD31 (bars = 50 μm). (E) Quantitative scores of
pathological abnormalities. (F) Mean number of infiltrating F4/80+ macrophages. (G) Mean number of CD31+ blood vessels in the synovium.
DAAP: Double-antiangiogenic protein; Tie2: Tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2; VEGF:
Vascular endothelial growth factor. The joint tissues were sampled at day 40. Values are mean ± SE, n = 18 to 20 for each group. *P < 0.05,
**P < 0.01 vs. Fc; #P < 0.05, ##P < 0.01 vs. VEGF-Trap.
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considerably lower than in DAAP- or VEGF-Trap-treated
mice. The RANKL expression of VEGF-Trap-treated CIA
mice was significantly lower than in mice treated with
DAAP or Tie2-Fc (Figure 4D). Taken together, these find-
ings demonstrate that DAAP suppresses synovial inflam-
mation, cartilage damage and bone destruction, primarily
by inhibiting angiogenesis rather than by directly decreas-
ing IL-1b, MMP-3 and RANKL.
Double-antiangiogenic protein shows therapeutic and
combination effects with etanercept in collagen-induced
arthritis
To further test the possible therapeutic effect of DAAP,
CIA mice that had begun developing arthritis were trea-
ted with either DAAP or Fc. DAAP-treated mice showed
significantly reduced progression of arthritis compared to
Fc-treated mice (Figure 5A). Additionally, combinatory
effects between DAAP and a relatively low dose of eta-
nercept (10 mg/kg) were tested and subsequently evalu-
ated. The effect of DAAP combined with etanercept was
significantly greater than that of either treatment alone
on arthritic progression in mice with established CIA
(Figure 5B).
VEGF-A, Ang-1 and Ang-2 show different temporal
patterns of expression during the course of collagen-
induced arthritis
These findings led us to further investigate why DAAP
is more effective than VEGF-Trap or Tie2-Fc alone in
the CIA model. Thus, joint extracts were isolated from
normal DBA1 and CIA mice in the early (day 26), active
(day 38) and chronic (day 52) phases and analyzed for
temporal patterns of expression of VEGF-A, Ang-1 and
Ang-2. In the early phase, Ang-1 and Ang-2 were
increased. In contrast, VEGF-A was not increased. In
the active phase, VEGF-A rose abruptly, Ang-1 contin-
ued to increase and Ang-2 decreased. In the chronic
phase, Ang-1 was persistently high despite decreased
VEGF-A (Figure 6). These results showed that the most
important angiogenic growth factors vary according to
the stage of CIA.
Discussion
In this study, we found that DAAP produces better protec-
tive effects on both inflammation and bone destruction in
CIA mice when compared with VEGF-Trap or Tie2-Fc.
These effects of DAAP were correlated with significantly
diminished pathologic abnormalities, CD31+ vasculature
and synovial infiltration by F4/80+ macrophages, suggest-
ing that DAAP acts primarily by inhibiting angiogenesis.
We further demonstrated the therapeutic effect of DAAP
and the beneficial combinatory effect of DAAP with TNF-
a inhibitor in the established CIA mice. These data pro-
vide evidence for the usefulness of DAAP, which simulta-
neously blocks VEGF-A and angiopoietins as an effective
new therapeutic agent for RA.
DAAP treatment showed more pronounced suppressive
effects on arthritis severity than VEGF-Trap or Tie2-Fc
alone in CIA mice. We propose the following explanations
for why and how DAAP is more effective than VEGF-
Trap or Tie2-Fc. First, arthritic synovium has strong
expression and activation levels of VEGF-A, PIGF, Ang-1
and Ang-2, and their expression patterns were different
according to disease stages of RA in our data and other
Figure 4 Effects of double-antiangiogenic protein on the production of matrix metalloprotease 3, interleukin 1b and receptor
activator of nuclear factor-B ligand in collagen-induced arthritis. (A) through (C) Comparative concentrations of serum matrix
metalloprotease 3 (MMP-3) and interleukin 1b (IL-1b), and the IL-1b of tissue extracts from the hind paws of collagen-induced arthritis (CIA) mice
injected with Fc, vascular endothelial growth factor (VEGF)-Trap, tyrosine kinase with immunoglobulin and epidermal growth factor homology
domain 2 (Tie2)-Fc or double-antiangiogenic protein (DAAP). (D) Receptor activator of nuclear factor-B ligand (RANKL) mRNA expression in the
synovium of knee joints. A representative gel image is shown (upper) together with a graph comparing the semiquantitative polymerase chain
reaction (PCR) data (lower). Values are presented as the mean relative density of the RANKL PCR product bands normalized to the
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) PCR product bands. In all experiments, n = 10 for each group. Values are mean ± SE.
*P < 0.05, **P < 0.01 vs. Fc.
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reports [15,24-27]. Our previous study showed that DAAP
is able to bind to VEGF-A, PIGF, Ang-1, Ang-2 and Ang-
3/Ang-4. In comparison, VEGF-Trap was able to bind
VEGF-A and PIGF but not any of the angiopoietins,
whereas Tie2-Fc was able to bind all angiopoietins tested,
but not VEGF-A and PIGF [22]. Second, the upregulation
of Ang-2 is part of an angiogenic rescue when only VEGF-
A/VEGFR2 signaling is blocked in tumor models [9,22].
Figure 5 Therapeutic and combination effects of double-antiangiogenic protein in collagen-induced arthritis. (A) Therapeutic effect of
double-antiangiogenic protein (DAAP). (B) Therapeutic effect of the combination of DAAP with etanercept. Following the development of
clinical arthritis (average visual arthritis score of 2) on day 26 (arrow), collagen-induced arthritis mice were randomized to receive intraperitoneal
injections of Fc, DAAP (25 mg/kg each every two days), etanercept (10 mg/kg every two days) or DAAP + etanercept (n = 8 or 9 mice for each
group). Values are mean ± SE. *P < 0.05, **P < 0.01 vs. Fc.
Figure 6 Vascular endothelial growth factor A, angiopoietin 1 and angiopoietin 2 show different temporal patterns of expression during
the course of collagen-induced arthritis. Collagen-induced arthritis (CIA) was induced, and joint extracts were isolated from normal DBA1 mice and
from early (day 26), active (day 38) and chronic (day 52) CIA mice (n = 4 for each group). (A) Representative sections of the ankle joints stained with
hematoxylin and eosin (bars = 500 μm) from normal DBA1 and early, active and chronic CIA mice. (B) Sequential changes in the expression levels of
angiopoietin 1 (Ang1) and Ang2 proteins in the joint tissue were determined by Western blot analysis. (C) The vascular endothelial growth factor A
(VEGF-A) concentration in the joint tissue was determined by enzyme-linked immunosorbent assays. Values are mean ± SE. *P < 0.05 vs. normal.
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Third, DAAP has a longer half-life than VEGF-Trap and
Tie2-Fc, and the binding of either VEGF-A or Ang-2 to
DAAP enhances additional binding of Ang-2 or VEGF-A
to DAAP. Thus, DAAP appears to distribute well in the
arthritic environment and to block VEGF-A and Ang-2 in
a synergistic manner [22]. Taken together, the simulta-
neous blockage of VEGF and angiopoietin signaling by
DAAP appears more effective in suppressing arthritis-
associated angiogenesis than blockage by VEGF-Trap or
Tie2-Fc separately.
Apart from its important function as a VEGF, angio-
poietin/Tie-2 signaling induces the proliferation of RA
synovial fibroblasts and promotes the proinflammatory
activation of macrophages [16,17]. Especially, angiopoie-
tin/Tie-2 signaling is an important mediator that links
the proinflammatory TNF-a to pathologic angiogenesis
[19,28]. VEGF-A aggravates joint destruction by directly
increasing the differentiation and activity of osteoclasts
[8,29]. In contrast, Ang1 can suppress osteoclast activity
indirectly via enhanced osteoblast maturation [30,31]. In
this study, MMP-3 and IL-1 levels were lower in the
Tie2-Fc-treated group than DAAP or VEGF-Trap, but
RANKL levels were lower in the VEGF-Trap-treated
group than in the DAAP or Tie2-Fc groups. Collectively,
these findings suggest that Tie2-Fc is more advanta-
geous for suppressing inflammation than VEGF-Trap
and that VEGF-Trap is more advantageous for prevent-
ing bone destruction than Tie2-Fc. DAAP is a chimeric
decoy receptor that can block both the VEGF/VEGF-R
and angiopoietin/Tie-2 pathways, simultaneously. Thus,
DAAP has suppressive effects on both inflammation and
bone destruction in CIA.
Numerous efforts to create a promising strategy for
treating cancer and inflammatory arthritis have focused on
disrupting the VEGF-A pathway [4,6]. Despite promising
results, recent clinical trials with cancer patients treated
with VEGF-A inhibitors have generated two puzzling
questions. First, the anti-VEGF-A strategy is insufficient
and evokes resistance. These findings reflect insufficient
improvements in clinical outcomes, including benefits lim-
ited to short-term survival and the development of adap-
tive resistance, intrinsic nonresponsiveness and the rapid
regrowth of tumor vessels after cessation of therapy [6,32].
In this regard, emerging evidence indicates that upregula-
tion of angiopoietins may be a major mechanism underly-
ing the inadequate therapeutic effects of VEGF-A pathway
blockage [9,22]. Second, a number of adverse effects have
been reported with anti-VEGF-A therapy, and some of
these toxicities can be explained by the use of high doses
of anti-VEGF-A [10,22]. Even though we administered a
lower molar dosage of DAAP than VEGF-Trap or Tie2-
Fc, DAAP displayed more pronounced effects. Therefore,
DAAP may show greater antiarthritic activity and less
toxicity than VEGF-Trap or Tie2-Fc in RA treatment.
Etanercept is a soluble TNF-a type II receptor linked
to an IgG1-Fc moiety that binds to and inactivates
TNF-a [33]. Although studies have demonstrated its
efficacy in reducing inflammation and joint destruction,
over 30% to 40% of anti-TNF-a-treated patients fail to
achieve a response, and efficacy is lost in many patients
during therapy [34,35]. Other shortcomings of anti-
TNF-a therapies include increased rates of infection and
malignancy [34]. In contrast, DAAP may be suitable to
effectively treat both tumors and arthritis with no
increased risk of infection. Our results showed the pos-
sible role of the combination of DAAP and TNF-a inhi-
bitors in slowing arthritic progression more than either
treatment alone. Therefore, DAAP may be used as a
synergistic as well as an alternative treatment for RA
patients who are responding poorly to a TNF-a blocking
agent and for those patients at high risk of infection or
malignancy.
This study has some limitations. Our previous study
showed that DAAP is superior to the combined therapy
of VEGF-Trap plus Tie2-Fc in suppressing tumor
growth, angiogenesis and metastasis [22]. Those findings
suggest that DAAP is also superior to the combined
therapy of VEGF-Trap plus Tie2-Fc in CIA mice. How-
ever, we did not conduct CIA experiments to compare
DAAP and the combined therapy of VEGF-Trap plus
Tie2-Fc. Additionally, we proved only the priority of
DAAP to be more effective than VEGF-Trap or Tie2-Fc
in the prevention of CIA, not in the therapeutic effect in
established CIA. Thus, further study is needed to prove
these effects.
Conclusions
We found that DAAP induces better protective effects
than VEGF-Trap or Tie2-Fc on both inflammation and
bone destruction in CIA mice. Additionally, we proved
that DAAP has therapeutic effects and a beneficial com-
bination effect with the TNF-a inhibitor on CIA. Our
results raise the possibility that the coordinated blocking
of angiogenic activities by DAAP might represent a pro-
mising and powerful strategy for the treatment of RA.
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